Clinical Trials Directory

Trials / Completed

CompletedNCT04822415

Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis

Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine for Inferior Alveolar Nerve Blocks in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
330 (actual)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block for patients with symptomatic irreversible pulpitis in mandibular molars.

Detailed description

The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block for patients with symptomatic irreversible pulpitis in mandibular molars. Patients were clinically and radiographically examined and their eligibility assessed and preoperative pain was measured using the numerical rating scale (NRS). Patients were randomly assigned to one of 2 groups: experimental group (2% mepivacaine) and the control group (4% articaine). After 15 minutes of the inferior alveolar nerve block (IANB), patients reporting lip numbness had their molars accessed. No-to-mild pain response was considered success during root canal preparation.

Conditions

Interventions

TypeNameDescription
DRUGMepivacaineIANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
DRUGArticaineIANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.

Timeline

Start date
2014-12-01
Primary completion
2016-12-01
Completion
2016-12-01
First posted
2021-03-30
Last updated
2021-08-02

Source: ClinicalTrials.gov record NCT04822415. Inclusion in this directory is not an endorsement.